Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
US6432679B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 10, 1999 |
| Grant date | Aug 13, 2002 |
| Priority date | — |
| Expiry date | Jun 10, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18534
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides vaccine adjuvants comprising the Epstein Barr Virus glycoprotein 350/220 or naturally occurring variants thereof, a fusion protein comprising EBV Gp350/220 sequence which binds to the CR2 receptor, or a synthetically-derived fragment of Gp350/220 which retains the ability to bind to the CR2 receptor. The present invention further provides immunostimulatory compositions comprising an EBV Gp350/220 adjuvant sequence that binds the CR2 complex and at least one antigen of interest other than Gp350/220. Co-administration of the adjuvant with an antigen of interest, other than an antigen comprising EBV 350/220 sequence, enhances the immunogenicitiy of the antigen. In a preferred embodiment, the adjuvant is directly or indirectly covalently bound to an antigen of interest to form an immunogenic composition. In a most preferred embodiment of the composition, antibodies are elicited against at least one Gp350/220 epitope and against at least one epitope of the antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.